ANGANY expands and redefines its executive team to better manage upcoming development stages.
Québec, Canada, November 2nd, 2023 – ANGANY announces the appointment of Christine Guillen, PharmD, as Chief Executive Officer. In this capacity, Ms. Guillen will sit on the Board of Directors. Her appointment follows a rigorous, collaborative multi-step recruitment process that began last spring.
ANGANY also announces the strengthening of its Executive Committee with the appointment of Mr. Patrick Colin, BPharm PhD, as Vice-President, Clinical Development, and Pr. Claude Favrot, DMV, as Vice-President, Veterinary Development.
A pharmacist by training, Ms. Guillen brings with her a solid expertise in biopharmaceuticals, as well as extensive experience in managing innovative life sciences companies. She joins the ANGANY team as the company reaches a turning point. With the start of clinical development of its next-generation biologic ANG-101 for the treatment of cat allergy, ANGANY must evolve its programs and operations. Ms. Guillen’s structured approach will accelerate the achievement of value milestones on ANGANY’s timetable.
Ms. Guillen says: “I’m delighted to take up the challenge of bringing a breakthrough technology to a tangible clinical and pharmaceutical reality. My role is to bring together the diverse and remarkable strengths of a great team on both sides of the Atlantic to change the lives of nearly a billion people affected by allergy and who deserve new therapeutic solutions that are safer, more effective and better adapted to their lifestyle. We’re privileged to have been able to recruit Patrick Colin and Claude Favrot, each an authority in his field thanks to their respective competence and experience. It’s very motivating to see the extent to which our technological approach and our initial collaboration have won their enthusiasm and commitment,” adds Christine Guillen.
Former CEO Louis-Philippe Vézina was instrumental in recruiting his successor and has been appointed Executive Chairman of the Board. Dr. Vézina will now focus his efforts on ANGANY’s scientific and technical development. “I’m convinced that Dr. Guillen’s background, experience, leadership and communication skills are ideally suited to ANGANY’s development as an emerging company,” says Dr. Vézina.
ANGANY is a Franco-Canadian private clinical-stage biotech company pioneering a new immunotherapy approach to overcome the challenge of allergy through breakthrough therapeutics. ANGANY’s eBioparticle™ technology makes for biologics of a new generation to be administered as vaccines. The goal is to restore or reinforce natural immune mechanisms and create lasting immune protection. ANGANY’s eBioparticle-Potentiated Immunotherapy™ also opens-up new prospects in several fields of application beyond allergy in human and animal health, notably in cancer immunotherapy. The company operates a cGMP pilot production unit in Quebec, as well as an R&D laboratory in France. ANGANY uses a flexible, efficient and easily scalable 3rd generation plant bioproduction platform to manufacture its next-generation biologics.
For more information: www.angany.com.
Media Relations :
Media consultant and Public relations
Relations aux investisseurs, autres demandes :
Guy Tropper MD FRCSC
Co-Founder and Executive Vice-President